A new meta-analysis indicates that multiple sclerosis disease-modifying therapies (DMTs) have positive effects on cognition. High-efficacy and medium-efficacy DMTs apparently had comparable cognitive benefits; however, limitations of the original studies, including brief duration, restricted assessment and failure to account for baseline cognitive impairment, might limit the interpretation of the findings.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Benedict, R. H. & Zivadinov, R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat. Rev. Neurol. 7, 332–342 (2011).
Amato, M. P., Krupp, L. B., Charvet, L. E., Penner, I. & Till, C. Pediatric multiple sclerosis: cognition and mood. Neurology 87, S82–S87 (2016).
Sotirchos, E. S. et al. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis. Mult. Scler. 26, 312–321 (2020).
Amato, M. P. et al. Association of neocortical volume changes with cognitive deterioration in relapsing–remitting multiple sclerosis. Arch. Neurol. 64, 1157–1161 (2007).
Landmeyer, N. C. et al. Disease-modifying treatments and cognition in relapsing–remitting multiple sclerosis: a meta-analysis. Neurology 94, e2373–e2383 (2020).
Kalb, R. et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult. Scler. 13, 1665–1680 (2018).
Rocca, M. A. et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 14, 302–317 (2015).
Montalban, X. et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24, 96–120 (2018).
Rae-Grant, A. et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis — report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90, 777–788 (2018).
Trojano, M. et al. Treatment decisions in multiple sclerosis — insights from real-world observational studies. Nat. Rev. Neurol. 13, 105–118 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.P.A. has received research grants from Biogen, Merck, Teva, Roche, Novartis and Sanofi Genzyme and honoraria as a speaker and advisory board member from Biogen, Merck, Teva, Roche, Novartis and Sanofi Genzyme. L.B.K. has received consulting fees, served on data and safety monitoring boards or received grant support from Biogen, Novartis, Sanofi and Genzyme, and has received licensing fees from various pharmaceutical and biomedical companies for the Fatigue Severity Scale.
Rights and permissions
About this article
Cite this article
Amato, M.P., Krupp, L.B. Disease-modifying therapy aids cognition in multiple sclerosis. Nat Rev Neurol 16, 525–526 (2020). https://doi.org/10.1038/s41582-020-0383-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-020-0383-x
